Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :101
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed156    
    Printed4    
    Emailed0    
    PDF Downloaded4    
    Comments [Add]    

Recommend this journal

 

 GI CANCER: ORIGINAL ARTICLE
Year : 2020  |  Volume : 57  |  Issue : 2  |  Page : 158-163

An analysis of adjuvant treatment strategies in operated pancreatic cancer patients: An Izmir oncology group study


1 Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey
2 Department of Internal Medicine, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey
3 Department of Radiation Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey
4 Department of Oncology Clinic, Manisa Government Hospital, Manisa, Turkey
5 Department of Institute of Oncology, Dokuz Eylul University, Izmir, Turkey

Correspondence Address:
Ahmet Alacacioglu
Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijc.IJC_318_18

Rights and Permissions

Background: Adjuvant treatment is necessary in pancreatic cancer patients, but the optimal approach is not clear yet. Our aim was to explore the effectiveness of adjuvant treatment modalities in patients with operated pancreatic cancer. Methods: There were five groups of patients operated for primary pancreas adenocarcinoma. The first two groups included patients who were treated with only adjuvant chemotherapy or radiotherapy. The patients in third group had received combination chemotherapy and radiotherapy either sequentially or concomitantly. The fourth group was composed of patients who were treated with adjuvant chemotherapy after concurrent chemoradiotherapy, whereas the patients in the fifth group were only observed after surgery without any adjuvant treatment. Results: There were 83 operated pancreatic cancer patients available for analysis. Median age of the patients was 63 years (range, 40–82 years). There were 55 patients who had local disease recurrence (n = 14) or metastasis (n = 41) during or after adjuvant treatment. The median overall survival for all patients was 14 months. When we compared the median survival of patients who had any adjuvant treatment with the patients treated without any adjuvant therapy, we found a significant statistical difference between the groups (32.4 vs 6.5 months; P = 0.000). In addition, survival of each treatment group was also compared with each other but we did not find any significant statistical difference. Conclusions: Our result suggests that any adjuvant therapy in the treatment of pancreatic cancer patients is important. However, we could not find any superiority between adjuvant treatment modalities.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow